Abstract. Hepatitis B virus (HBV) is the dominant risk factor for hepatocellular carcinoma (HCC). HBV X protein (HBx) plays crucial roles in HCC carcinogenesis. HBx interferes with several signaling pathways including the Notch1 pathway in HCC. In this study, we found that Notch1 was highly expressed in HCC, especially in large HCCs. Notch1 and HBx co-localized in HCC and their levels were positively correlated with each other. Notch1 expression was more elevated in HepG2.2.15 cells than that in HepG2 cells. HBx activated the Notch1 pathway in HepG2.2.15 cells. Suppression of HBx and the Notch1 pathway attenuated the growth of HepG2.2.15 cells. Notch1, ERK, and AKT pathways were inhibited after γ-secretase inhibitor treatment. Dual-specificity phosphatase 1 (DUSP1) and phosphatase and tensin homolog (PTEN) were upregulated after γ-secretase inhibitor treatment and Hes1 inhibition. Luciferase reporter assays showed that Hes1 suppressed the promoters of DUSP1 and PTEN genes, which was reversed by γ-secretase inhibitor treatment. Western blotting demonstrated that DUSP1 dephosphorylated pERK and PTEN dephosphorylated pAKT. Collectively, we found a link among HBx, the Notch1 pathway, DUSP1/PTEN, and ERK/AKT pathways, which influenced HCC cell survival and could be a therapeutic target for HCC treatment.
Introduction
Hepatocellular carcinoma (HCC) remains a major health concern worldwide (1). Hepatitis B virus (HBV) is the dominant risk factor for HCC (2) , accounting for more than half of all cases (3) . HBV X protein (HBx) is the only expressed HBV protein and plays critical roles in hepatocarcinogenesis (4) . Previous reports have shown that HBx interferes with many signal transduction pathways including Hippo, nuclear factor-κB, WNT/β-catenin, and p53 pathways (2, (4) (5) (6) (7) . However, the molecular mechanisms underlying the hepatocellular carcinogenesis induced by HBx remain unclear.
The Notch pathway plays crucial roles in organogenesis and morphogenesis, and influences various biological processes including apoptosis, proliferation, and differentiation (8) . Emerging evidence demonstrates that dysregulation of the Notch pathway is associated with various types of malignancies (9, 10) . Persistent activation of the Notch pathway leads to liver malignancies (11) . A link between HBx and the Notch pathway has been reported previously (12, 13) . Studies have demonstrated that HBx activates the Notch1 pathway that further upregulates ERK and AKT pathways to promote cell proliferation (14, 15) . However, the detailed molecular mechanisms whereby Notch1 activates ERK and AKT pathways in HCC are unresolved.
In this study, we further explored the link between HBx and Notch1 in HCC and elucidated the molecular mechanisms underlying Notch1/ERK and Notch1/AKT activations by HBx.
Materials and µethods
Patients and clinical specimens. A total of 121 human liver tissue samples were collected from patients who underwent surgical resections at the Hepatic Surgery Centre, Tongji Hospital of Huazhong University of Science and Technology (Wuhan, China). Detailed clinicopathological parameters are listed in Table I . The procedure of human specimen collection was approved by the Ethics Committee of Tongji Hospital, Huazhong University of Science and Technology, and the study was conducted according to the Declaration of Helsinki. Immunohistochemical analysis. Immunohistochemistry (IHC) was performed as described previously (16) . Primary antibodies against HBx and Notch1 were purchased from Merck-Millipore (Billerica, MA, USA) and Santa Cruz Biotechnology (Santa Cruz, CA, USA), respectively.
Western blotting. Western blotting was performed as described previously (17) . The primary antibodies and their sources were as follows: anti-Notch1, anti-Hes1, anti-NICD, anti-pERK, anti-ERK, and anti-pAKT (Cell Signaling Technology, Beverly, MA, USA); anti-Jagged1, anti-β-actin, anti-AKT, and anti-DUSP1 (Santa Cruz Biotechnology); anti-HBx (Merck-Millipore); anti-PTEN (Proteintech Group, Chicago, IL, USA). Horseradish peroxidase-conjugated secondary antibodies were purchased from Jackson Immuno Research Laboratories (West Grove, PA, USA).
Double immunofluorescence analysis. Double immuno-
fluorescence immunostaining was performed as described previously (18, 19) . Double-labeling immunofluorescence was used to detect HBx and Notch1 simultaneously. All sections were analyzed by confocal laser-scanning microscopy using a Nikon Digital Eclipse C1 system (Nikon Corp., Japan).
Reverse transcription and real-time quantitative PCR (qPCR)
analysis. PCR was performed as described previously (20) . The primer sequences for HBx were as follows: sense, 5'-GGC TGCTAGGCTGTGCTGCC-3'; antisense, 5'-GTTCCTGTGG GCGTTCACG G-3'. Images of electrophoresed PCR products were acquired using the Alpha Innotech Fluorochem Imaging system. Real-time PCR primers are listed in Table II Transient RNA interference. Small interfering RNA (siRNA) duplexes targeting human HBx, Hes1, DUSP1, and PTEN sequences and a scrambled siRNA were designed as described previously (5, (21) (22) (23) . All siRNAs were synthesized by Ribobio (Guangzhou, China). Transfection of the siRNA duplexes was performed by jetPRIME (Polyplus-transfection SA, Illkirch, France) according to the manufacturer's instructions.
Cell viability assay. The cell viability assay was performed as described previously (24) . HepG2.2.15 cells (2x10 3 per well) were seeded and cultured in 96-well plates for the indicated times. Cell Counting Kit-8 (CCK-8, Dojindo, Japan) was added to the cells, and the optical density value at 450 nm was measured after 2 h.
Transcriptional response assay. Luciferase assays were performed as described previously (25) . Cell lysates was subjected to luciferase assays using the Dual-luciferase Reporter assay system (Promega) according to the manufacturer's instructions. DUSP1-luc reporter, PTEN-luc reporter, and Hes1 expression vectors were transfected as reported Table Ⅰ . Correlation between the factors and clinicopathological parameters in HCC patients (n=121). previously (26) (27) (28) . Relative luciferase activities were determined by a Glomar 20/20 Illuminometer (Promega) and normalized against Renilla luciferase as an internal control.
Chromatin immunoprecipitation (ChIP).
Quantitative ChIP analysis was performed as described previously (29) . Briefly, cells were crosslinked, sonicated, and immunoprecipitated with anti-Hes1 antibodies or IgG (negative control). A mixture of two anti-Hes1 antibodies (H140, Santa Cruz Biotechnology; 4H1, Novus Biologicals) was used for immunoprecipitation. Then, DNA was eluted and crosslinking was reversed, followed by purification and amplification for PCR analysis.
The primers used in qPCR are listed in Table III .
Statistical analysis. Data were analyzed using GraphPad Prism 5.0 (La Jolla, CA, USA) or SPSS 13.0 (Chicago, IL, USA). All experiments were independently performed at least three times. The results are presented as the mean ± standard error of the mean. Comparisons between different groups were evaluated by one-way analysis of variance. P<0.05 was considered as statistically significant. 
Results

Expression of Notch1 in human liver and HCC tissues.
Immunohistochemical analysis showed that Notch1 was highly expressed in HCC tissues. Notch1 also exhibited expression in adjacent non-tumor and cirrhosis tissues. However, its expression was significantly lower than that in HCC tissues (P<0.01). Moreover, the expression of Notch1 in normal liver tissues was significantly lower than that in the above-mentioned tissues (P<0.001) (Fig. 1A and B) . Western blotting showed similar results (Fig. 1C) . In most HCC tissues, the expression of Notch1 was highly elevated compared with that in the other tissues. Notch1 was weakly expressed in all normal liver tissues. Specifically, among 121 HCC tissues, 19 of them had weak expression and 102 of them had high expression. In the 121 corresponding peritumoral tissues, 59 of them had weak expression and 62 of them had high expression (P<0.001) (Table IV) . Table I shows the correlation between the factors and clinicopathological parameters in the 121 HCC patients. As shown in the table, sex, age, and the AFP level were unrelated to Notch1 expression. The level of Notch1 was significantly more elevated in HBV-positive patients (P<0.001), cirrhosis patients, (P<0.05), and patients with large HCCs (P<0.05).
Co-localization and relationship of Notch1 with HBx in HCC tissues and the HepG2.2.15 cell line.
Previous reports have shown the relationship of Notch1 with HBx. Here, we found co-localization of the two proteins. IHC results showed that Notch1 and HBx were co-expressed in HCC tissues ( Fig. 2A) . Fig. 2B shows the correlation of Notch1 and HBx expression levels. Spearman's rho was 0.584, indicating that Notch1 levels were positively correlated with HBx expression in the 108 HBV-positive HCC tissues. Fig. 2C shows HBx (green) and Notch1 (red) staining in HepG2.2.15 cells. The yellow staining in dual labeling (Fig. 3A and B ). Next, we tested the expression of some members of the Notch1 pathway, such as Jagged1, Notch1, and Hes1. Western blotting showed that the protein levels of the three proteins were much more elevated in HepG2.2.15 cells than in HepG2 cells (Fig. 3B) . Next, we knocked down HBx expression in HepG2.2.15 cells by HBx-specific siRNA. Western blotting and PCR confirmed that HBx expression was significantly decreased by the siRNA (Fig. 3C and D) . Western blotting showed that the decrease of HBx expression led to a decrease of Notch1 and Hes1 expression in HepG2.2.15 cells (Fig. 3D) , verifying that HBx regulated the expression of Notch1 in vitro.
Suppression of HBx and the Notch1 pathway inhibits the growth of HepG2.2.15 cells. Our results indicated that
Notch1 was highly expressed in HCC tissues, especially in large HCC tissues, and the Notch1 pathway was regulated by HBx, we therefore determined whether inhibition of (Fig. 3G) . Our data showed that DAPT treatment greatly inhibited the growth of HepG2.2.15 cells. Therefore, we tested expression of ERK and AKT pathways that are closely related to cell proliferation. Western blotting indicated that DAPT greatly reduced the amount of pERK and pAKT in a time-dependent manner, but did not have any effect on total ERK or AKT (Fig. 3H) .
Upregulation of DUSP1 and PTEN after DAPT treatment in
HepG2.2.15 cells. Previous reports have revealed the regulatory circuit linking the pathway with DUSP1 expression and ERK activity (21) . A link has also been found between the Notch1 pathway and PTEN and AKT activities (28) . Our data showed that DUSP1 and PTEN were upregulated after DAPT treatment in HepG2.2.15 cells by western blotting (Fig. 3I and J) . (Fig. 4A) . Growth of HepG2.2.15 cells was inhibited after SiHes1 treatment (Fig. 4B) . Next, we found that the mRNA levels of DUSP1 and PTEN were greatly increased after SiHes1 treatment ( Fig. 4C and D) . Western blot analysis showed the same results. The Hes1 protein level was significantly reduced and the protein levels of DUSP1 and PTEN were elevated significantly (Fig. 4E) .
Upregulation of DUSP1 and PTEN after
Hes1 suppresses and directly binds to the promoters of DUSP1 and PTEN genes in HepG2.2.15 cells.
Based on the above data, we investigated whether Hes1 suppressed DUSP1 and PTEN. We performed DUSP1 and PTEN promoter assays using a luciferase reporter. The basal activities of DUSP1 and PTEN gene promoters were reduced by Hes1. Treatment of Fig. 4F and G) . We next performed ChIP assays to determine whether Hes1 directly bound to the promoters of DUSP1 and PTEN genes using two mixed antibodies against Hes1. We designed several primers in the promoter regions of DUSP1 and PTEN genes (Fig. 5) . ChIP assays showed that Hes1 bound to the regulatory sequences in the promoters of DUSP1 and PTEN genes in HepG2.2.15 cells (Fig. 6A and B) . Quantitative ChIP assays revealed significant enrichment of two regions of the DUSP1 and PTEN gene promoters compared with control IgG immunoprecipitation, which was reversed by treatment with DAPT ( Fig. 6C and D Fig. 7A and B) . We then evaluated the effect of PTEN inhibition on AKT phosphorylation. Treatment with SiPTEN effectively decreased PTEN mRNA and protein levels, which induced an increase of the pAKT level ( Fig. 7C and D) . The above findings demonstrated that DUSP1 dephosphorylated pERK and PTEN dephosphorylated pAKT.
Discussion
Notch1 is overexpressed in HCC (14) . Consistent with the results of previous studies, we found that Notch1 expression in tumor tissues was much more elevated than that in peritumoral, cirrhosis, and normal tissues by IHC and western blot analyses. Previous reports have shown co-localization of Notch1 with HBx (14) . In our study, we found that inhibition of the Notch1 pathway downregulated the phosphorylated levels of ERK and AKT. Previous studies have shown that Hes1, the key member of the Notch1 pathway, represses expression of DUSP1 that is active against pERK in non-small cell lung carcinoma (21) . Another study has shown that Hes1 decreases expression of PTEN, a negative regulator of the AKT pathway in T-cell leukemia (28) . Thus, we hypothesized that the pathway influenced expression of DUSP1 and PTEN, and further affected ERK and AKT pathways in HepG2.2.15 cells. To test this hypothesis, we performed PCR, western blotting, luciferase assays, and ChIP. We found that mRNA and protein levels of DUSP1 and PTEN were increased after Hes1 inhibition. To investigate the mechanisms that link inhibition of the Notch1 pathway with dephosphorylation of ERK and AKT, we analyzed the transcriptional changes induced by DAPT. Promoter induction of DUSP1 and PTEN genes after DAPT treatment were confirmed in HepG2.2.15 cells. Previous data have shown that ERK and AKT pathways are important to regulate the Notch1 pathway downstream of HBx. However, a direct link between Notch1 and ERK/AKT pathways has not been revealed (15) .
Hes1 is a well-known transcriptional regulator of multiple genes (30, 31) . Based on our finding that the Hes1 level was reduced upon DAPT treatment of HepG2.2.15 cells, we hypothesized that dephosphorylation of ERK or AKT induced by DAPT could be regulated by Hes1-mediated decreases of DUSP1 or PTEN. Our luciferase reporter assays showed that Hes1 was a negative regulator of DUSP1 and PTEN. It directly repressed DUSP1 and PTEN gene promoters, which was reversed by DAPT treatment. Next, we found that increased levels of pERK and pAKT were induced by inhibition of DUSP1 and PTEN, respectively. This result could explain the decrease in ERK and AKT phosphorylations upon DAPT treatment.
In conclusion, this study explored a direct link among HBx, the Notch1 pathway, DUSP1/PTEN, and ERK/AKT pathways (Fig. 8) . We found that HBx activated the Notch1 pathway to promote cell growth, which was correlated with the capacity of Hes1 to increase ERK/AKT activities through decrease of DUSP1/PTEN expression. Nevertheless, we cannot exclude that other molecular mechanisms might take part in mediating the effects of DAPT. Therefore, the underlying mechanisms need to be elucidated further.
